GuidelineThe Lancet. Oncology2020
Hereditary diffuse gastric cancer: updated clinical practice guidelines.
Open access · greenAbstract readPractice GuidelineReview
In one paragraph
Guideline in The Lancet. Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 243 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
243citing papers in PubMed, 2 pooled it
40.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
243 citing papers in PubMed, 2 syntheses or guidelines pooled it, 462 citations in OpenAlex.
- Asian Pacific Association of Gastroenterology task force recommendations on surveillance forGut · 2026Guideline
- Updated European guidelines for clinical management of familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS) and other rare adenomatous polyposis syndromes: a joint EHTG-ESCP revision.The British journal of surgery · 2024Guideline
- Non-invasive screening in hereditary cancer: a randomized controlled trial to test cell-free DNA-based early detection in the CHARM consortium.European journal of human genetics : EJHG · 2026Trial
- The origins and progression of pyloric metaplasia following gastric mucosal injury.Physiological reviews · 2026Review
- Hereditary diffuse gastric cancer in progress: Comparative lessons from Lynch syndrome.European journal of human genetics : EJHG · 2026Review
- Early-onset adenocarcinomas of the distal esophagus, gastroesophageal junction, and stomach: a systematic review and meta-analysis of 45 studies.ESMO gastrointestinal oncology · 2026Review
- Exome sequencing points to pathogenic ATM variants in gastric cancer.European journal of human genetics : EJHG · 2026Article
- Bilateral Prophylactic and Contralateral Risk-Reducing Mastectomy in Women With Germline CDH1 Pathogenic or Likely-Pathogenic Variants.Journal of surgical oncology · 2026Review
- Optimising rare tumour risk syndromes care: clinical insights and the PREVENTABLE socioeconomic framework.European journal of human genetics : EJHG · 2026Article
- Germline whole-exome sequencing identifies CTNND1 as a candidate gene for hereditary gastric cancer in a large Brazilian cohort.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Variant-specific functional effects of CTNNA1 in a humanized Drosophila model.European journal of human genetics : EJHG · 2026Article
- Multidisciplinary Management Considerations in Invasive Lobular Breast Cancer: It Isn't Just Ductal.Annals of surgical oncology · 2026Article
- Genetic Counseling in Aotearoa New Zealand: Context, Practice and the Future of Genomic Healthcare.Journal of genetic counseling · 2026Article
- Inherited cancer syndromes in adult oncology: a referral guide based on malignant tumor and polyp features.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Endoscopic detection of signet ring cell carcinoma in CDH1 carriers: a 15-year single-centre experience.Familial cancer · 2026Article
- Predictors of early cancer burden inEClinicalMedicine · 2026Article
- Radiomics in Gastric Cancer: Advancing Precision Medicine.Journal of gastric cancer · 2026Review
- Stomach and beyond: imaging the linitis plastica phenotype in signet ring cell carcinoma.Abdominal radiology (New York) · 2026Review
- Article
- Mapping the genetic landscape of hereditary diffuse-type gastric cancer progression.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
183 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
66 authors at 20 institutions in 12 countries.
Vanessa R BlairDepartment of Surgery, University of Auckland, Auckland, New Zealand; St Marks Breast Centre, Auckland, New Zealand.
Maybelle McLeodKimihauora Health and Research Clinic, Mt Maunganui, New Zealand.
Fátima CarneiroInstituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal.
Daniel G CoitMemorial Sloan Kettering Cancer Center and Weill Cornell Medical School, New York, NY, USA.
Johanna L D'AddarioHereditaryDiffuseGastricCancer.org, Madison, WI, USA.
Jolanda M van DierenDepartment of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
Kirsty L HarrisBrisbane, QLD, Australia.
Nicoline HoogerbruggeDepartment of Human Genetics, Radboud University Medical Centre, Nijmegen, Netherlands.
Carla OliveiraInstituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal.
Rachel S van der PostDepartment of Pathology, Radboud University Medical Centre, Nijmegen, Netherlands.
Julie ArnoldNew Zealand Familial Gastrointestinal Cancer Service, Auckland Hospital, Auckland, New Zealand.
Patrick R BenusiglioConsultation d'Oncogénétique, Unité Fonctionnelle d'Oncogénétique, Département de Génétique, DMU BioGeM, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Université, Paris, France.
Tanya M BisselingDepartment of Gastroenterology, Radboud University Medical Centre, Nijmegen, Netherlands.
Alex BoussioutasDepartment of Medicine, Royal Melbourne Hospital and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Annemieke CatsDepartment of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
Amanda CharltonDepartment of Histopathology, Auckland Hospital, Auckland, New Zealand.
Karen E Chelcun SchreiberHereditaryDiffuseGastricCancer.org, Madison, WI, USA.
Jeremy L DavisCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Massimiliano di PietroMedical Research Council Cancer Unit, University of Cambridge, Cambridge, UK.
Rebecca C FitzgeraldMedical Research Council Cancer Unit, University of Cambridge, Cambridge, UK.
James M FordDivision of Oncology, Departments of Medicine and Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Kimberley GametGenetic Health Service New Zealand Northern Hub, Auckland Hospital, Auckland, New Zealand.
Irene GulloInstituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal.
Richard H HardwickCambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK.
David G HuntsmanDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Pardeep KaurahDepartment of Medical Genetics, University of British Columbia, Vancouver, BC, Canada; Hereditary Cancer Program, British Columbia Cancer, Vancouver, BC, Canada.
Sonia S KupferSection of Gastroenterology, Nutrition and Hepatology, University of Chicago, Chicago, IL, USA.
Andrew LatchfordSt Mark's Hospital, London, UK; Department of Cancer and Surgery, Imperial College, London, UK.
Paul F MansfieldUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
Takeshi NakajimaDepartment of Clinical Genetic Oncology, Cancer Institute Hospital, Tokyo, Japan.
Susan ParryNew Zealand Familial Gastrointestinal Cancer Service, Auckland Hospital, Auckland, New Zealand.
Jeremy RossaakDepartment of Surgery, Tauranga Hospital, Tauranga, New Zealand.
Haruhiko SugimuraDepartment of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Magali SvrcekSorbonne Université, Assistance Publique-Hôpitaux de Paris, Department of Pathology, Hôpital Saint-Antoine, Paris, France.
Marc TischkowitzDepartment of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
Toshikazu UshijimaDivision of Epigenomics, National Cancer Centre Research Institute, Tokyo, Japan.
Hidetaka YamadaDepartment of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Han-Kwang YangSeoul National University Hospital, Seoul, South Korea.
Adrian ClaydonDepartment of Gastroenterology, Tauranga Hospital, Tauranga, New Zealand.
Joana FigueiredoInstituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal.
Karyn ParingataiTe Tumu School of Māori, Pacific and Indigenous Studies, University of Otago, Dunedin, New Zealand.
Raquel SerucaInstituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal.
Nicola Bougen-ZhukovCancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand.
Tom BrewCancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand.
Simone BusijaNo Stomach for Cancer, Madison, WI, USA.
Patricia CarneiroInstituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal.
Lynn DeGregorioDeGregorio Family Foundation, New York, NY, USA.
Helen FisherBrisbane, QLD, Australia.
Erin GardnerKimihauora Health and Research Clinic, Mt Maunganui, New Zealand.
Tanis D GodwinCancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand.
Katharine N HolmDepartment of Biochemistry and Molecular Medicine, University of California Davis School Of Medicine, Davis, CA, USA.
Bostjan HumarLaboratory of the Swiss Hepato-Pancreato-Biliary and Transplantation Centre, Department of Surgery, University Hospital Zürich, Zurich, Switzerland.
Caroline J LintottGenetic Health Service New Zealand South Island Hub, Christchurch Hospital, Christchurch, New Zealand.
Elizabeth C MonroeDeGregorio Family Foundation, New York, NY, USA.
Mark D MullerMt Maunganui, New Zealand.
Enrique NoreroEsophagogastric Surgery Unit, Digestive Surgery Department, Hospital Dr Sotero del Rio, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Yasmin NouriCancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand.
Joana ParedesInstituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal.
João M SanchesInstitute for Systems and Robotics, Instituto Superior Técnico, Lisbon, Portugal.
Emily SchulpenCancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand.
Ana S RibeiroInstituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal.
Andrew SporleHealthier Lives National Science Challenge, University of Otago, Dunedin, New Zealand.
James WhitworthDepartment of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
Liying ZhangDepartment of Pathology and Laboratory Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Anthony E ReeveCancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand.
Parry GuilfordCancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry, University of Otago, Dunedin, New Zealand. Electronic address: parry.guilford@otago.ac.nz.
University of Otago · NZi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · PTAuckland City Hospital · NZRadboud University Medical Center · NLHamamatsu University School of Medicine · JPHereditary Disease Foundation · USTauranga Hospital · NZThe Netherlands Cancer Institute · NLUniversity of British Columbia · CAUniversity of Cambridge · GBWhakauae Research (New Zealand) · NZAssistance Publique – Hôpitaux de Paris · FRChristchurch Hospital · NZImperial College London · GBINESC TEC · PTMedical Research Council · GBMemorial Sloan Kettering Cancer Center · USNational Cancer Centre Japan · JPNational Health Service · GBNational Institute for Health Research · GB
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FRANCESCA M GANY · 1985 to 2026
$347.4MMedical Research Council MC_UU_12022/2NCI NIH HHS P30 CA008748
Abstract
Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome that is characterised by a high prevalence of diffuse gastric cancer and lobular breast cancer. It is largely caused by inactivating germline mutations in the tumour suppressor gene CDH1, although pathogenic variants in CTNNA1 occur in a minority of families with HDGC. In this Policy Review, we present updated clinical practice guidelines for HDGC from the International Gastric Cancer Linkage Consortium (IGCLC), which recognise the emerging evidence of variability in gastric cancer risk between families with HDGC, the growing capability of endoscopic and histological surveillance in HDGC, and increased experience of managing long-term sequelae of total gastrectomy in young patients. To redress the balance between the accessibility, cost, and acceptance of genetic testing and the increased identification of pathogenic variant carriers, the HDGC genetic testing criteria have been relaxed, mainly through less restrictive age limits. Prophylactic total gastrectomy remains the recommended option for gastric cancer risk management in pathogenic CDH1 variant carriers. However, there is increasing confidence from the IGCLC that endoscopic surveillance in expert centres can be safely offered to patients who wish to postpone surgery, or to those whose risk of developing gastric cancer is not well defined.
Indexed as
Neoplastic Syndromes, HereditaryStomach NeoplasmsHumans
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.